IP Verse

Vaccine Against Porcine Parvovirus And Porcine Reproductive And Respiratory Syndrome Virus And Methods Of Production Thereof - EP3534939

The patent EP3534939 was granted to Boehringer Ingelheim Vetmedica on Feb 22, 2023. The application was originally filed on Nov 2, 2017 under application number EP17808328A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3534939

BOEHRINGER INGELHEIM VETMEDICA
Application Number
EP17808328A
Filing Date
Nov 2, 2017
Status
Opposition Rejected
Sep 5, 2025
Publication Date
Feb 22, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ZOETIS SERVICESNov 21, 2023PAGEADMISSIBLE

Patent Citations (64) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS19860920197
DESCRIPTIONUS19960675556
DESCRIPTIONUS19960675566
DESCRIPTIONCN102488895
DESCRIPTIONCN102727881
DESCRIPTIONCN104288760
DESCRIPTIONEP0265785
DESCRIPTIONEP0370573
DESCRIPTIONEP2460818
DESCRIPTIONRU2004108484
DESCRIPTIONUS2014322267
DESCRIPTIONUS2015283229
DESCRIPTIONUS2909462
DESCRIPTIONUS382425
DESCRIPTIONUS4394448
DESCRIPTIONUS4603112
DESCRIPTIONUS4722848
DESCRIPTIONUS4745051
DESCRIPTIONUS4769330
DESCRIPTIONUS4769331
DESCRIPTIONUS4945050
DESCRIPTIONUS5174993
DESCRIPTIONUS5338683
DESCRIPTIONUS5364773
DESCRIPTIONUS5494807
DESCRIPTIONUS5505941
DESCRIPTIONUS5552143
DESCRIPTIONUS5580859
DESCRIPTIONUS5589466
DESCRIPTIONUS5591439
DESCRIPTIONUS5591639
DESCRIPTIONUS5677178
DESCRIPTIONUS5762938
DESCRIPTIONUS5770212
DESCRIPTIONUS5928913
DESCRIPTIONUS5942235
DESCRIPTIONUS7700285
DESCRIPTIONWO2006072065
DESCRIPTIONWO2007094893
DESCRIPTIONWO2013024113
DESCRIPTIONWO9001543
DESCRIPTIONWO9011092
DESCRIPTIONWO9111525
DESCRIPTIONWO9319183
DESCRIPTIONWO9416716
DESCRIPTIONWO9421797
DESCRIPTIONWO9511307
DESCRIPTIONWO9520660
DESCRIPTIONWO9530018
DESCRIPTIONWO9639491
DESCRIPTIONWO9800166
DESCRIPTIONWO9833510
INTERNATIONAL-SEARCH-REPORTCN102488895
INTERNATIONAL-SEARCH-REPORTCN102727881
INTERNATIONAL-SEARCH-REPORTCN104288760
INTERNATIONAL-SEARCH-REPORTEP2460818
INTERNATIONAL-SEARCH-REPORTRU2004108484
INTERNATIONAL-SEARCH-REPORTUS2014322267
INTERNATIONAL-SEARCH-REPORTUS2015283229
INTERNATIONAL-SEARCH-REPORTUS7700285
INTERNATIONAL-SEARCH-REPORTWO2013024113
OPPOSITIONUS2012213810
OPPOSITIONWO2011028888
OPPOSITIONWO2018083156

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Javier L?pez-Vidal ET AL, "Improved Production Efficiency of Virus-Like Particles by the Baculovirus Expression Vector System", PLOS ONE, (20151012), vol. 10, no. 10, doi:10.1371/journal.pone.0140039, page e0140039, XP055376600
OPPOSITION- Anonymous, "Guideline on the requirements for combined vaccines and associations of immunological veterinary medicinal products (IVMPs)", European Medicines Agency (EMA); EMA/CVMP/IWP/594618/2010 Committee for Medicinal Products for Veterinary Use (CVMP), (20130718), European Medicines Agency (EMA); EMA/CVMP/IWP/594618/2010 Committee for Medicinal Products for Veterinary Use (CVMP) , (20240322), XP093144718
OPPOSITION- Anonymous , "VP2 [Porcine parvovirus]", PROTEIN, URL: NCBI, XP093144717
OPPOSITION- CASAL J I, "USE OF PARVOVIRUS-LIKE PARTICLES FOR VACCINATION AND INDUCTION OF MULTIPLE IMMUNE RESPONCES", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, Humana Press Inc, New York, New York , (19990401), vol. 29, ISSN 0273-2289, pages 141 - 150, XP002162594
OPPOSITION- Reply 2021
OPPOSITION- Rowe Raymond C, Sheskey Paul J, Marian E. Quinn, "Carbomer. Hypromellose. Polycarbophil", Handbook of Pharmaceutical Excipients, Pharmaceutical Press, (20090101), pages 110 - 509-512, XP093031841
OPPOSITION- Tiago Vicente; Antnio Roldo; Cristina Peixoto; Manuel J.T. Carrondo; Paula M. Alves;, "Large-scale production and purification of VLP-based vaccines", Journal of invertebrate pathology, SAN DIEGO, CA, US, US , vol. 107, doi:10.1016/j.jip.2011.05.004, ISSN 0022-2011, pages S42 - S48, XP028244445
OPPOSITION- Renukaradhya Gourapura J.; Meng Xiang-Jin; Calvert Jay G.; Roof Michael; Lager Kelly M., "Live porcine reproductive and respiratory syndrome virus vaccines: Current status and future direction", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (19000101), vol. 33, no. 33, doi:10.1016/j.vaccine.2015.06.092, ISSN 0264-410X, pages 4069 - 4080, XP029250554
OPPOSITION- Rueda, P. Fominaya, J. Langeveld, J.P.M. Bruschke, C. Vela, C. Casal, J.I., "Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles", Vaccine, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20001122), vol. 19, no. 7-8, doi:10.1016/S0264-410X(00)00259-0, ISSN 0264-410X, pages 726 - 734, XP004225389

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents